Sentinel lymph node biopsy in endometrial cancer: state of the art.
Sentinel lymph node (SLN)
endometrial cancer (EC)
paraaortic lymph node
pelvic lymph node
tracers
ultrastaging
Journal
Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
22
02
2020
accepted:
07
04
2020
entrez:
4
2
2022
pubmed:
1
12
2020
medline:
1
12
2020
Statut:
ppublish
Résumé
Endometrial cancer (EC) is the most common gynecological neoplasm in developed countries. In literature, there are discordant data regarding the therapeutic value of systematic lymphadenectomy whereas the importance of lymph node status for determining prognosis and the need for adjuvant treatment is undoubted. Given the low risk of lymph-node metastases in the apparent early-stage disease and the significant surgical and postoperative risks when performing a complete pelvic lymphadenectomy, the surgical approach in these patients is controversial, ranging from no nodal evaluation to comprehensive pelvic and aortic lymphadenectomy. The recent introduction of sentinel node mapping represents the mid-way between the execution and omission of node dissection in EC patients. Indeed, the sentinel node mapping has rapidly emerged as an alternative to complete lymphadenectomy to reduce morbidity. In the present review, we discuss the role of sentinel node mapping in the surgical management of EC evaluating all aspects of this procedure.
Identifiants
pubmed: 35117375
doi: 10.21037/tcr.2020.04.21
pii: tcr-09-12-7725
pmc: PMC8797296
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
7725-7733Informations de copyright
2020 Translational Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr.2020.04.21). The series “Endometrial Cancer” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.
Références
Gynecol Oncol. 2012 Jul;126(1):5-11
pubmed: 22555109
Ann Surg Oncol. 2016 Aug;23(8):2522-8
pubmed: 26905542
Arch Gynecol Obstet. 2019 Feb;299(2):299-315
pubmed: 30542793
Int J Gynecol Cancer. 2013 Jun;23(5):964-70
pubmed: 23694985
Am J Obstet Gynecol. 1985 Apr 15;151(8):1009-15
pubmed: 3985062
Am J Obstet Gynecol. 2017 Jun;216(6):594.e1-594.e13
pubmed: 28213057
Cochrane Database Syst Rev. 2017 Jan 04;1:CD004561
pubmed: 28052186
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Gynecol Oncol. 2008 Nov;111(2 Suppl):S44-50
pubmed: 18760450
Gynecol Oncol. 2004 Feb;92(2):669-74
pubmed: 14766264
Int J Gynecol Pathol. 2018 May;37(3):242-251
pubmed: 28700425
Gynecol Oncol. 2008 Sep;110(3):286-92
pubmed: 18653219
Int J Gynecol Cancer. 2008 Mar-Apr;18(2):269-73
pubmed: 18334008
Int J Gynecol Cancer. 2015 Oct;25(8):1513-8
pubmed: 26397069
Gynecol Oncol. 2015 Aug;138(2):478-85
pubmed: 26047592
Cancer. 1987 Oct 15;60(8 Suppl):2035-41
pubmed: 3652025
Gynecol Oncol. 2013 Sep;130(3):452-6
pubmed: 23774300
Gynecol Oncol. 2015 Sep;138(3):497-500
pubmed: 26232339
Arch Gynecol Obstet. 2017 Sep;296(3):565-570
pubmed: 28744616
Am J Obstet Gynecol. 2004 Aug;191(2):435-9
pubmed: 15343218
J Obstet Gynaecol Can. 2005 Dec;27(12):1107-12
pubmed: 16524529
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
Lancet. 2010 Apr 3;375(9721):1165-72
pubmed: 20188410
Int J Gynecol Cancer. 2013 Nov;23(9):1704-11
pubmed: 24177256
J Minim Invasive Gynecol. 2017 Jan 1;24(1):89-93
pubmed: 27725278
Ann Surg Oncol. 2016 Oct;23(11):3749-3756
pubmed: 27160526
Int J Gynecol Pathol. 2019 Jan;38(1):52-58
pubmed: 28968296
Eur J Surg Oncol. 2014 Jul;40(7):843-9
pubmed: 24613744
Int J Gynecol Cancer. 2015 Mar;25(3):521-5
pubmed: 25621410
Gynecol Oncol. 2012 Jun;125(3):531-5
pubmed: 22366409
Eur J Gynaecol Oncol. 2002;23(1):53-7
pubmed: 11876394
Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1163-8
pubmed: 18217960
J Obstet Gynaecol Res. 2014 Feb;40(2):327-34
pubmed: 24620369
Gynecol Oncol. 2012 Sep;126(3):419-23
pubmed: 22659192
Gynecol Oncol. 2009 May;113(2):296-7; author reply 297
pubmed: 19167050
Asian Pac J Cancer Prev. ;18(2):431-435
pubmed: 28345826
Gynecol Oncol. 2015 Sep;138(3):542-7
pubmed: 26095896
Gynecol Oncol. 2009 Nov;115(2):236-8
pubmed: 19666190
Minim Invasive Ther Allied Technol. 2020 Aug;29(4):232-239
pubmed: 31169418
Updates Surg. 2017 Mar;69(1):75-82
pubmed: 28108938
Gynecol Oncol. 2012 Oct;127(1):5-10
pubmed: 22771890
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Updates Surg. 2017 Mar;69(1):29-34
pubmed: 28188573
Obstet Gynecol. 2006 Dec;108(6):1375-9
pubmed: 17138769
Gynecol Oncol. 2017 Aug;146(2):240-246
pubmed: 28577885
Gynecol Oncol. 2011 Dec;123(3):522-7
pubmed: 21945553
Oncotarget. 2017 Jul 11;8(28):46601-46610
pubmed: 28410225
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Clin Nucl Med. 2016 Dec;41(12):927-932
pubmed: 27749429
Int J Gynecol Cancer. 2014 Jul;24(6):1048-53
pubmed: 24927249
Int J Gynecol Cancer. 2015 Jul;25(6):1044-50
pubmed: 25853384
Lancet Oncol. 2016 Jun;17(6):757-767
pubmed: 27161539
Gynecol Oncol. 2007 Jan;104(1):100-3
pubmed: 16963111
Arch Gynecol Obstet. 2019 Jul;300(1):169-174
pubmed: 31006842
Gynecol Oncol. 2009 Dec;115(3):453-5
pubmed: 19767064
Ann Surg Oncol. 2016 Jan;23(1):196-202
pubmed: 25994210
Am J Obstet Gynecol. 2016 Jul;215(1):117.e1-7
pubmed: 26743505
Gynecol Oncol. 2015 Jun;137(3):443-7
pubmed: 25771495
Gynecol Oncol. 2011 Apr;121(1):122-5
pubmed: 21194737
Nucl Med Rev Cent East Eur. 2014;17(2):55-8
pubmed: 25088102
Ann Surg Oncol. 2017 Jun;24(6):1660-1666
pubmed: 28058558
J Natl Compr Canc Netw. 2018 Feb;16(2):170-199
pubmed: 29439178
Obstet Gynecol. 2014 Aug;124(2 Pt 1):307-315
pubmed: 25004343
Gynecol Oncol. 2007 May;105(2):457-61
pubmed: 17313975
J Cancer Res Clin Oncol. 2017 Oct;143(10):2039-2048
pubmed: 28828528
Am J Obstet Gynecol. 2017 May;216(5):459-476.e10
pubmed: 27871836